echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Beda Pharmaceuticals cooperates with Universal Gene to add coded gene detection and tumor-targeted drugs

    Beda Pharmaceuticals cooperates with Universal Gene to add coded gene detection and tumor-targeted drugs

    • Last Update: 2021-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Beda Pharmaceuticals announced on the morning of the 27th that the company and Hangzhou Rip Gene Technology Co., Ltd. intend to sign a "strategic cooperation agreement" in the near future. On the same day, the Company disclosed that it intends to acquire a 77.4091% stake in Kananji for 37,156.368 million yuan.
    said in the announcement, based on individual gene level precision medicine is gradually becoming the mainstream of clinical tumor prevention and treatment, through genetic testing to accurately find the cause of the disease and treatment targets, and ultimately achieve the goal of individual precision treatment of diseases and specific patients. Targeted treatment for NSCLC has also been recommended to include EGFR testing in the specification, EGFR detection is rapidly popular. In view of the importance of genetic testing for precision medicine and the real needs of lung cancer patients for EGFR testing, the company intends to sign a Strategic Cooperation Agreement with Rip Gene in the near future, and the two sides will strengthen cooperation in the field of precision medicine on the basis of equality, mutual benefit and complementarity of advantages.
    Kananji Pharmaceutical Technology (Shanghai) Co., Ltd. is a high-tech start-up specializing in new drug research and development in Shanghai Free Trade Pilot Zone, with a registered capital of RMB691,266.5 million, and is currently mainly engaged in research and development of targeted new drug CM082 ("CM082"). CM082 is a small molecule targeted at VEGFR and PDGFR targets for new drugs, clinical dosage form for oral tablets. CM082 not only has significant efficacy for VEGFR and PDGFR targets, but also overcomes the high toxic side effects common to this class of targeted drugs, and ongoing clinical studies include single-drug trials for age-related under-eye macular degeneration and trials of CM082 and Ivemos combined drugs to treat renal transparent cell carcinoma.
    In January 2015, Kananji received a clinical approval for the treatment age-related wet eye ophthalmology project I/II/III issued by the State Food and Drug Administration, and started the CM082 Clinical Phase I trial in China at Huaxi Hospital of Sichuan University in February 2015, which has been gradually extended to Peking University People's Hospital, Shanghai First People's Hospital, Beijing Hospital and Beijing Tongren Hospital. In December 2016, the clinical IIB phase trial of the targeted new drug CM082 and Evimos was launched at Beijing Cancer Hospital.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.